Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation

Transplant Immunology

Volumn 11, Issue 3-4, 2003, Pages 307-321

  Mathew, James M ^a   Garcia Morales, Rolando O ^a   Carreno, Manuel ^a   Jin, Yide ^a   Fuller, Laphalle ^a   Blomberg, Bonnie ^a   Cirocco, Robert ^a   Burke, George W ^a   Ciancio, Gaetano ^a   Ricordi, Camillo ^a   Esquenazi, Violet ^a,b   Tzakis, Andreas G ^a   Miller, Joshua ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Donor bone marrow cells (DBMC); Immune responses; Living related donor (LRD)

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RECOMBINANT INTERLEUKIN 2; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ACUTE GRAFT REJECTION; ADOPTIVE IMMUNOTHERAPY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ASSAY; B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CADAVER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL COUNT; CELL FUNCTION; CELL INTERACTION; CELL STIMULATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CHIMERA; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; EFFECTOR CELL; EPSTEIN BARR VIRUS; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; ILIAC CREST; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MULTIPLE MYELOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; SPLEEN CELL; STEM CELL; SUPPRESSOR CELL; SURVIVAL; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

EID: 10744223680     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(03)00056-X     Document Type: Article

References (64)

1. Slavin S, Nagler A, Shapira M, Panigrahi S, Samuel S, Or A. Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Crit Rev Oncol Hematol 2001;39(1-2):25-29.
2. Billingham RE, Brent L, Medawar PB. 'Actively acquired tolerance' of foreign cells. Nature 1953;172:603-606.
3. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978;299:799-803.
4. Salvatierra O Jr., Vincenti F, Amend W, et al. Deliberate donor-specific blood transfusions prior to living-related renal transplantation. Ann Surg 1980;192:543-552.
5. Slavin S, Fuks Z, Strober S, Kaplan H, Howard RJ, Sutherland DE. Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation. Transplantation 1979;28:359-361.
6. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice: VII. Optimal cellular antigen for induction of immunologic tolerance with ALS. Transplant Proc 1970;2:489-496.
7. Caridis DT, Liegeois A, Barrett I, Monaco AP. Enhanced survival of canine renal allografts of ALS-treated dogs given bone marrow. Transplant Proc 1973;5:671-674.
8. Thomas JM, Carver FM, Foil MB. Renal allograft tolerance induced with ATG and donor bone marrow in out-bred rhesus monkeys. Transplantation 1983;36:104-106.
9. Wood K, Sachs DH. Chimerism and transplantation tolerance: Cause and effect. Immunol Today 1996;17:584-587.
10. Monaco AP, Clark AW, Wood ML, et al. Possible active enhancement of a human cadaver renal allograft with anti-lymphocyte serum (ALS) and donor bone marrow: Case report of an initial attempt. Surgery 1976;79:384-392.
11. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaver renal allograft recipients. Transplantation 1991;51:70-75.
12. McDaniel DO, Naftilan J, Hulvey K, et al. Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation 1994;57:852-856.
13. Fontes P, Rao AS, Demetris AJ, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart and pancreas islet transplantation. Lancet 1994;344:151-155.
14. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole organ transplantation: The basis of graft acceptance. Hepatology 1993;17:1127-1152.
15. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002;73(9):1386-1391.
16. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68(4):480-484.
17. Trivedi HL, Shah VR, Vanikar AV, et al. High-dose peripheral blood stem cell infusion: A strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients. Pediatr Transplant 2002;6(1):63-68.
18. Ricordi C, Karatzas T, Selvaggi G, et al. Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ann NY Acad Sci 1995;770:345-350.
19. Garcia-Morales R, Carreno M, Mathew JM, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997;99:1118-1129.
20. Garcia-Morales R, Carreno M, Mathew JM, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998;65:956-965.
21. Miller J, Mathew JM, Garcia-Morales R, et al. The human bone marrow as an immunoregulatory organ. Transplantation 1999;68:1079-1090.
22. Ciancio G, Miller J, Garcia-Morales R, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001;71:827-835.
23. Ciancio G, Burke GW, Garcia-Morales R, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation 2002;74(4):488-496.
24. Chatzipetrou MA, Mathew JM, Kenyon NS, et al. Analysis of post-transplant immune status in recipients of liver/bone marrow allografts. Hum Immunol 1999;60:1281-1288.
25. Garcia-Morales R, Esquenazi V, Zucker K, et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996;62:1149-1160.
26. Elwood ET, Larsen CP, Maurer DH, et al. Microchimerism and rejection in clinical transplantation. Lancet 1997;349(9062):1358-1360.
27. Sivasai KSR, Alevy Y, Duffy B, et al. Peripheral blood microchimerism in human liver and renal transplant recipients: Rejection despite donor-specific chimerism. Transplantation 1997;64:427-432.
28. Sivasai KSR, Jendrisak M, Duffy DC, et al. Chimerism in the peripheral blood of sensitized patients waiting for renal transplantation: Clinical implications. Transplantation 2000;69:538-544.
29. Schlitt HJ, Hundrieser J, Ringe B, Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med 1994;330:646-647.
30. O'Neill PA, Lawler M, Pullens R, et al. PCR amplification of short tandem repeat sequences allows serial studies of chimerism/engraftment following BMT in rodents. Bone Marrow Transplant 1996;17:265-271.
31. Van Tol MJ, Langlois Van Den Bergh R, Mesker W, et al. Simultaneous detection of X and Y chromosomes by two-color fluorescence in situ hybridization in combination with immunophenotyping of single cells to document chimerism after sex-mismatched bone marrow transplantation. Bone Marrow Transplant 1998;21:497-503.
32. Pei R, Chen T, Orpilla J, Lee JH. A simultaneous negative and positive selection method that can detect chimerism at a frequency of 1 per 10 000 by flow cytometry. Tissue Antigens 1997;50:197-201.
33. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity 1952;6:201-221.
34. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945;102:400-401.
35. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity and genetic specificity of tolerance. J Exp Med 1985;162:231-244.
36. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989;169:493-502.
37. Mathew JM, Garcia-Morales R, Fuller L, et al. Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses. Transplantation 2000;70:1675-1682.
38. Larsen CP, Austyn JM, Morris PJ. The role of graft-derived dendritic leukocytes in the rejection of vascularized organ allografts. Recent findings on the migration and function of dendritic leukocytes after transplantation. Ann Surg 1990;212:308-315.
39. Starzl TE, Demetris AJ, Rao AS, et al. Migratory non-parenchymal cells after organ allotransplantation: With particular reference to chimerism and the liver. Prog Liver Dis 1994;12:191-213.
40. Rugeles MT, Aitouche A, Zeevi A, et al. Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation 1997;64:735-741.
41. Burlingham WJ, Grailer AP, Fechner JH Jr., et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995;59:1147-1155.
42. Mathew JM, Fuller L, Carreno M, et al. Involvement of multiple subpopulations of human bone marrow cells in the regulation of allogeneic cellular immune responses. Transplantation 2000;70:1752-1760.
43. Davies JD, Leong LY, Mellor A, et al. T cell suppression in transplantation tolerance through linked recognition. J Immunol 1996;156:3602-3607
44. Miller RG. An immunological suppressor cell which inactivates cytotoxic T lymphocyte precursor cells recognizing it. Nature 1980;287:544-546.
45. Thomas JM, Verbanac KM, Carver FM, et al. Veto cells in transplant tolerance. Clin Transplant 1994;8:195-203.
46. Lagoo-Deenadayalan S, Lagoo AS, Lemons JA, et al. Donor-specific bone marrow cells suppress lymphocyte reactivity to donor antigens and differentially modulate TH1 and TH2 cytokine gene expression in the responder cell population. Transplant Immunol 1995;3:124-134.
47. Ierino FL, Yamada K, Hatch T, Rembert J, Sachs DH. Peripheral tolerance to class I mismatched renal allografts in miniature swine: Donor antigen-activated peripheral blood lymphocytes from tolerant swine inhibit antidonor CTL reactivity. J Immunol 1999;162(1):550-559.
48. Rachamim N, Gan J, Segall H, et al. Tolerance induction by 'megadose' hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998;65(10):1386-1393.
49. Mathew JM, Carreno M, Fuller L, et al. Modulatory effects of human donor bone marrow cells on allogeneic cellular immune responses. Transplantation 1997;63:686-692.
50. Mathew JM, Carreno M, Zucker K, et al. Cellular immune responses of human cadaver donor bone marrow cells and their susceptibility to commonly used immunosuppressive drugs in transplantation. Transplantation 1998;65:947-955.
51. Dejbakhsh-Jones S, Garcia-Ojeda ME, Chatterjea-Matthes D, Zeng D, Strober S. Clonable progenitors committed to the T lymphocyte lineage in the mouse bone marrow; Use of an extrathymic pathway. Proc Natl Acad Sci (USA) 2001;98(13):7455-7460.
52. Matthew JM, Carreno M, Fuller L, et al. In vitro immunogenicity of cadaver donor bone marrow cells used for the induction of allograft acceptance in clinical transplantation. Transplantation 1999;68(8):1172-1180.
53. Geha RS, Gatien JG, Parkman R, Crain JD, Rosen FS, Merler E. Discontinuous density gradient analysis of human bone marrow: Presence of alloantigen-responsive, PHA-unresponsive cells in normal bone marrow; Absence of B lymphocytes in the bone marrow of patients with X-linked agammaglobulinemia. Clin Immunol Immunopathol 1974;2(3):404-415.
54. Pinna AD, Weppler D, Berho M, et al. Unusual presentation of graft-vs.-host disease in pediatric liver transplant recipients: Evidence of late and recurrent disease. Pediatr Transplant 1999;3:236-242.
55. Mathew JM, Carreno M, Fuller L, et al. Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation 2002;74(6):846-855.
56. Jin Y, Fuller L, Esquenazi V, et al. Bone marrow cells inhibit the generation of autologous EBV-specific CTL. Hum Immunol 2000;61(6):538-547.
57. Jin Y, Fuller L, Wei Y, Blomberg BB, Miller J, Esquenazi V. Bone marrow cells promote TH2 polarization and inhibit virus-specific CTL generation. Hum Immunol 2000;61(12):1233-1241.
58. - T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 2001;182:201-206.
59. +) depleted bone marrow cells. Hum Immunol 2002;63(7):567-575.
60. Carreno MR, Fuller L, Mathew JM, et al. Human donor bone marrow cells induce in vitro 'suppressor T cells' that functionally suppress autologous B cells. Hum Immunol 2003;64(1):21-30.
61. Mathew JM, Miller J. Immunoregulatory role of chimerism in clinical organ transplantation. Bone Marrow Transplant 2001;28:115-119.
62. Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000;164:4465-4470.
63. Jiang S, Tugulea S, Pennesi G, et al. Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Hum Immunol 1998;59:690-699.
64. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70(6):887-895.